Curis Company Profile (NASDAQ:CRIS)

About Curis (NASDAQ:CRIS)

Curis logoCuris, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CRIS
  • CUSIP: 23126910
  • Web: www.curis.com
Capitalization:
  • Market Cap: $257.29 million
  • Outstanding Shares: 143,878,000
Average Prices:
  • 50 Day Moving Avg: $1.81
  • 200 Day Moving Avg: $2.12
  • 52 Week Range: $1.47 - $3.72
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.93
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $8.31 million
  • Price / Sales: 27.18
  • Book Value: $0.06 per share
  • Price / Book: 26.17
Profitability:
  • EBIDTA: ($48,510,000.00)
  • Net Margins: -836.18%
  • Return on Equity: -236.43%
  • Return on Assets: -88.44%
Debt:
  • Debt-to-Equity Ratio: 4.33%
  • Current Ratio: 3.72%
  • Quick Ratio: 3.72%
Misc:
  • Average Volume: 580,589 shs.
  • Beta: 1.9
  • Short Ratio: 9.59
 

Frequently Asked Questions for Curis (NASDAQ:CRIS)

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The company had revenue of $2.10 million for the quarter, compared to analyst estimates of $2.08 million. Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. Curis's revenue was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.09) earnings per share. View Curis' Earnings History.

When will Curis make its next earnings announcement?

Curis is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Curis.

Where is Curis' stock going? Where will Curis' stock price be in 2017?

3 brokers have issued 1-year price targets for Curis' shares. Their forecasts range from $6.00 to $7.00. On average, they anticipate Curis' share price to reach $6.50 in the next twelve months. View Analyst Ratings for Curis.

What are analysts saying about Curis stock?

Here are some recent quotes from research analysts about Curis stock:

  • 1. According to Zacks Investment Research, "Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. " (7/17/2017)
  • 2. Cowen and Company analysts commented, "In our view, recent underperformance of CRIS shares is not reflective of the continued." (5/5/2017)

Who are some of Curis' key competitors?

Who are Curis' key executives?

Curis' management team includes the folowing people:

  • James R. McNab Jr., Independent Chairman of the Board
  • Ali Fattaey Ph.D., President, Chief Executive Officer, Director
  • James E. Dentzer, Chief Financial Officer, Chief Administrative Officer
  • Mani Mohindru Ph.D., Senior Vice President, Chief Strategy Officer
  • David Tuck M.D., Chief Medical Officer
  • Lori A. Kunkel M.D., Director
  • Martyn D. Greenacre, Independent Director
  • Kenneth I. Kaitin Ph.D., Independent Director
  • Robert E. Martell M.D., Ph.D., Independent Director
  • Kenneth J. Pienta M.D., Independent Director

Who owns Curis stock?

Curis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Eagle Investment Management LLC (16.70%), FMR LLC (10.45%), Vanguard Group Inc. (3.45%), State Street Corp (1.29%), Northern Trust Corp (0.93%) and Royal Bank of Canada (0.66%). Company insiders that own Curis stock include Daniel R Passeri, Discovery Technologie Aurigene, James R Mcnab, Kenneth I Kaitin and Martyn D Greenacre. View Institutional Ownership Trends for Curis.

Who sold Curis stock? Who is selling Curis stock?

Curis' stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., TIAA CREF Investment Management LLC, Teachers Advisors LLC, FMR LLC, California State Teachers Retirement System, Janney Montgomery Scott LLC, ProShare Advisors LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Curis.

Who bought Curis stock? Who is buying Curis stock?

Curis' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., BB&T Securities LLC, State of Wisconsin Investment Board, Alliancebernstein L.P., OxFORD Asset Management LLP, Northern Trust Corp and Royal Bank of Canada. View Insider Buying and Selling for Curis.

How do I buy Curis stock?

Shares of Curis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Curis' stock price today?

One share of Curis stock can currently be purchased for approximately $1.57.


MarketBeat Community Rating for Curis (NASDAQ CRIS)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  328
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Curis (NASDAQ:CRIS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.50 (314.01% upside)

Analysts' Ratings History for Curis (NASDAQ:CRIS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$6.00LowView Rating Details
10/12/2016Royal Bank Of CanadaSet Price TargetBuy$7.00N/AView Rating Details
9/7/2016Robert W. BairdReiterated RatingOutperform$7.00N/AView Rating Details
3/1/2016SunTrust Banks, Inc.Initiated CoverageBuy$3.00N/AView Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$5.00N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Curis (NASDAQ:CRIS)
Earnings by Quarter for Curis (NASDAQ:CRIS)
Earnings History by Quarter for Curis (NASDAQ CRIS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.09)N/AView Earnings Details
8/3/2017Q2 2017($0.09)($0.10)$2.08 million$2.10 millionViewListenView Earnings Details
5/4/2017Q1 17($0.09)($0.11)$1.98 million$2.13 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.10)($0.08)$1.97 million$2.40 millionViewListenView Earnings Details
11/3/2016Q316($0.10)($0.21)$1.84 million$1.80 millionViewListenView Earnings Details
8/4/2016Q216($0.09)($0.09)$2.05 million$1.70 millionViewListenView Earnings Details
5/9/2016Q116($0.08)($0.07)$2.30 million$1.70 millionViewListenView Earnings Details
2/29/2016Q415($0.12)($0.10)$2.98 million$2.10 millionViewListenView Earnings Details
11/9/2015Q315($0.08)($0.04)$2.82 million$2.00 millionViewN/AView Earnings Details
8/6/2015Q215($0.06)($0.06)$3.50 million$2.10 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$2.27 million$1.17 millionViewN/AView Earnings Details
2/24/2015Q4 14($0.07)($0.07)$2.69 million$2.00 millionViewN/AView Earnings Details
11/10/2014Q314($0.05)($0.06)$4.13 million$1.80 millionViewN/AView Earnings Details
8/7/2014Q214($0.06)($0.02)$3.46 million$4.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.07)($0.06)$1.88 million$1.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.08)($0.05)$1.59 million$1.52 millionViewN/AView Earnings Details
11/5/2013Q313($0.01)($0.02)$6.44 million$7.20 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.05)($0.02)$4.43 million$5.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.05)($0.06)$3.86 million$0.90 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.08)($0.15)$2.07 million$1.69 millionViewN/AView Earnings Details
11/6/2012Q312($0.08)($0.04)$1.01 million$0.60 millionViewN/AView Earnings Details
8/2/2012($0.05)($0.04)ViewN/AView Earnings Details
5/8/2012$0.02$0.03ViewN/AView Earnings Details
10/27/2011($0.07)($0.05)ViewN/AView Earnings Details
7/28/2011($0.07)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Curis (NASDAQ:CRIS)
2017 EPS Consensus Estimate: ($0.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.08)($0.08)($0.08)
Q2 20171($0.07)($0.07)($0.07)
Q3 20171($0.07)($0.07)($0.07)
Q4 20171($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Curis (NASDAQ:CRIS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Curis (NASDAQ:CRIS)
Insider Ownership Percentage: 4.07%
Institutional Ownership Percentage: 44.72%
Insider Trades by Quarter for Curis (NASDAQ:CRIS)
Institutional Ownership by Quarter for Curis (NASDAQ:CRIS)
Insider Trades by Quarter for Curis (NASDAQ:CRIS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/5/2017James R McnabDirectorSell76,276$2.04$155,603.04View SEC Filing  
5/2/2017James R McnabDirectorSell116,708$2.38$277,765.04View SEC Filing  
4/27/2017James R McnabDirectorSell146,694$2.61$382,871.34View SEC Filing  
4/24/2017James R McnabDirectorSell110,322$2.59$285,733.98View SEC Filing  
9/7/2016Discovery Technologie AurigeneMajor ShareholderBuy10,208,333$2.40$24,499,999.20View SEC Filing  
5/27/2016Martyn D GreenacreDirectorSell15,000$1.69$25,350.00View SEC Filing  
5/26/2016Kenneth I KaitinDirectorSell15,000$1.76$26,400.00View SEC Filing  
12/30/2015Daniel R. PasseriDirectorSell14,400$3.01$43,344.00View SEC Filing  
12/29/2015Daniel R. PasseriDirectorSell11,200$2.91$32,592.00View SEC Filing  
12/28/2015Daniel R. PasseriDirectorSell13,600$2.85$38,760.00View SEC Filing  
12/23/2015Daniel R. PasseriDirectorSell48,900$2.78$135,942.00View SEC Filing  
12/21/2015Daniel R. PasseriDirectorSell289,000$2.99$864,110.00View SEC Filing  
8/27/2014Ali Ph.D. FattaeyCEOBuy62,890$1.60$100,624.00View SEC Filing  
12/11/2013Ali Ph.D. FattaeyCOOBuy3,000$2.52$7,560.00View SEC Filing  
11/12/2013Michael GrayCFOBuy10,000$2.86$28,600.00View SEC Filing  
11/8/2013Kenneth PientaDirectorBuy20,000$2.95$59,000.00View SEC Filing  
8/16/2013James McnabDirectorSell50,000$4.00$200,000.00View SEC Filing  
12/6/2012Daniel R PasseriCEOBuy25,000$3.03$75,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Curis (NASDAQ:CRIS)
Latest Headlines for Curis (NASDAQ:CRIS)
Source:
DateHeadline
globenewswire.com logoCuris to Present at the Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 23 at 2:38 AM
finance.yahoo.com logoCuris to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 22 at 4:32 PM
americanbankingnews.com logoComparing Curis (CRIS) & Idera Pharmaceuticals (IDRA)
www.americanbankingnews.com - September 21 at 4:48 AM
americanbankingnews.com logoCuris, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.17 Million
www.americanbankingnews.com - September 21 at 3:18 AM
americanbankingnews.com logoCuris, Inc. (CRIS) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - September 19 at 4:24 PM
finance.yahoo.com logoWhy Curis Inc (CRIS) Could Be A Buy
finance.yahoo.com - September 18 at 10:31 PM
americanbankingnews.com logoCuris, Inc. (CRIS) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - September 16 at 7:08 PM
globenewswire.com logoCuris Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
www.globenewswire.com - September 15 at 10:58 PM
finance.yahoo.com logoCuris Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 14 at 6:20 PM
seekingalpha.com logoCuris prices stock offering but doesn't disclose price
seekingalpha.com - September 14 at 9:25 AM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: September 13, 2017
seekingalpha.com - September 14 at 5:11 AM
globenewswire.com logoCuris Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - September 13 at 6:48 PM
finance.yahoo.com logoCuris Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 13 at 6:47 PM
finance.yahoo.com logoAurigene, a Wholly Owned Subsidiary of Dr. Reddy’s, and Curis Announce CA-170 Program Update Following Data Presented at ESMO 2017
finance.yahoo.com - September 12 at 6:13 PM
streetinsider.com logoCuris (CRIS) & Aurigene Report CA-170 Program Update Following ... - StreetInsider.com
www.streetinsider.com - September 11 at 6:11 PM
finance.yahoo.com logoCuris and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017
finance.yahoo.com - September 11 at 6:11 PM
seekingalpha.com logoCuris (CRIS) Presents At Baird's 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 7 at 5:39 PM
globenewswire.com logoCuris to Present at the Baird 2017 Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 6 at 10:33 PM
finance.yahoo.com logoCuris to Present at the Baird 2017 Global Healthcare Conference
finance.yahoo.com - September 6 at 5:32 PM
americanbankingnews.com logoCuris, Inc. (CRIS) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 6 at 2:28 AM
finance.yahoo.com logoETFs with exposure to Curis, Inc. : September 6, 2017
finance.yahoo.com - September 6 at 12:06 AM
nasdaq.com logoDo Options Traders Know Something About Curis (CRIS) Stock We Don't?
www.nasdaq.com - September 5 at 7:06 PM
finance.yahoo.com logoDo Options Traders Know Something About Curis (CRIS) Stock We Don't?
finance.yahoo.com - September 5 at 7:06 PM
americanbankingnews.com logoCuris, Inc. (CRIS) Lifted to Hold at ValuEngine
www.americanbankingnews.com - September 3 at 4:32 PM
streetinsider.com logoCuris (CRIS) Announces CA-170 Poster Presentation at ESMO
www.streetinsider.com - September 1 at 10:52 PM
streetinsider.com logoCuris (CRIS) Announces CA-170 Poster Presentation at ESMO - StreetInsider.com
www.streetinsider.com - August 31 at 10:25 PM
globenewswire.com logoCuris Announces CA-170 Poster Presentation at ESMO 2017 Congress - GlobeNewswire (press release)
globenewswire.com - August 31 at 5:24 PM
finance.yahoo.com logoCuris Announces CA-170 Poster Presentation at ESMO 2017 Congress
finance.yahoo.com - August 31 at 5:24 PM
finance.yahoo.com logoETFs with exposure to Curis, Inc. : August 25, 2017
finance.yahoo.com - August 25 at 9:01 PM
americanbankingnews.com logoCuris, Inc. (CRIS) Upgraded by BidaskClub to Sell
www.americanbankingnews.com - August 20 at 1:54 PM
finance.yahoo.com logoCuris, Inc. :CRIS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
finance.yahoo.com - August 16 at 5:54 PM
americanbankingnews.com logoCuris (CRIS) and GTx (GTXI) Head to Head Analysis
www.americanbankingnews.com - August 15 at 6:08 PM
americanbankingnews.com logo-$0.09 EPS Expected for Curis, Inc. (NASDAQ:CRIS) This Quarter
www.americanbankingnews.com - August 13 at 6:10 PM
americanbankingnews.com logoCuris, Inc. (NASDAQ:CRIS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 12 at 2:32 AM
rttnews.com logoEARNINGS SUMMARY: Details of Curis Inc Q2 Earnings Report
www.rttnews.com - August 4 at 5:47 PM
finance.yahoo.com logoEdited Transcript of CRIS earnings conference call or presentation 3-Aug-17 12:30pm GMT
finance.yahoo.com - August 4 at 5:47 PM
americanbankingnews.com logoCuris, Inc. (CRIS) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - August 3 at 8:32 PM
fool.com logoHere's Why Curis, Inc. Dropped as Much as 14.5% This Morning - Motley Fool
www.fool.com - August 3 at 4:28 PM
finance.yahoo.com logoCuris Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 4:28 PM
finance.yahoo.com logoHere's Why Curis, Inc. Dropped as Much as 14.5% This Morning
finance.yahoo.com - August 3 at 4:28 PM
finance.yahoo.com logoCuris reports 2Q loss
finance.yahoo.com - August 3 at 4:28 PM
rttnews.com logoCara Therapeutics Appoints Mani Mohindru As CFO
www.rttnews.com - August 1 at 6:14 PM
americanbankingnews.com logo Analysts Anticipate Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.06 Million
www.americanbankingnews.com - July 28 at 5:21 PM
globenewswire.com logoCuris to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017 - GlobeNewswire (press release)
globenewswire.com - July 27 at 10:49 PM
nasdaq.com logoCuris to Release Second Quarter 2017 Financial Results and Hold ... - Nasdaq
www.nasdaq.com - July 26 at 6:04 PM
finance.yahoo.com logoCuris to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017
finance.yahoo.com - July 26 at 6:04 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Curis, Inc. (CRIS) to Announce -$0.09 EPS
www.americanbankingnews.com - July 26 at 12:29 PM
americanbankingnews.com logoCuris, Inc. (CRIS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 18 at 1:53 PM
americanbankingnews.com logoCuris, Inc. (CRIS) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 17 at 8:26 PM
bizjournals.com logoTechnical Insights on Biotech Stocks -- Curis, OvaScience, Regulus Therapeutics, and Vanda Pharma
www.bizjournals.com - July 12 at 11:14 PM

Social

Chart

Curis (CRIS) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff